Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839776 | 0.95 | PTGS2 (0.83) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL830784 | 0.90 | PTGS2 (0.75) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL9188865 | 0.85 | PTGS2 (0.61) | PTGS2ALDH1A1MAPTKMT2ACYP2C9 | |
| SCHEMBL9188689 | 0.83 | ALDH1A1 (0.56) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL8485548 | 0.83 | PTGS2 (0.65) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL831162 | 0.82 | PTGS2 (0.65) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL11605368 | 0.81 | PTPN7 (0.69) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL8832017 | 0.81 | GAA (0.66) | PTGS2ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL3026910 | 0.80 | PTGS2 (0.62) | PTGS2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL656776 | 0.80 | PTGS2 (0.66) | PTGS2ALDH1A1MAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534894-B2 | Biphenyloxy-acids | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1667959-A1 | BIPHENYLOXY-ACIDS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060020003-A1 | Biphenyloxy-acids | WYETH (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2005030702-A1 | BIPHENYLOXY-ACIDS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020003-A1 | Biphenyloxy-acids | AHR, ARNT, NR1H4 | PTGS2 2391/4885ALDH1A1 388/4885MAPT 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.